Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

导出 OA

翻译打印收藏纠错

作者： Yong Gu,Lee ^[1] ; Puneeth,Guruprasad ^[2] ; Guido,Ghilardi ^[3] ; Raymone,Pajarillo ^[1] ; Christopher Tor,Sauter ^[2] ; Ruchi,Patel ^[1] ; Hatcher J,Ballard ^[2] ; Seok Jae,Hong ^[1] ; Inkook,Chun ^[2] ; Nicholas,Yang ^[1] ; Kimberly V,Amelsberg ^[2] ; Katherine D,Cummins ^[1] ; Jakub,Svoboda ^[2] ; Saar,Gill ^[1] ; Elise A,Chong ^[4] ; Khrystyna,North ^[1] ; Sarah E,Church ^[2] ; Joseph A,Fraietta ^[1] ; Wan-Jung,Chang ^[2] ; Simon F,Lacey ^[1] ; Xueqing Maggie,Lu ^[2] ; Yunlin,Zhang ^[1] ; Kanupriya,Whig ^[2] ; David C,Schultz ^[1] ; Sara,Cherry ^[2] ; James,Gerson ^[1] ; Stephen J,Schuster ^[4] ; Patrizia,Porazzi ^[1] ; Marco,Ruella ^[2]

作者单位： Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. ^[1] Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. ^[2] College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea. ^[3] Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. ^[4] NanoString Technologies Inc., Seattle, Washington. ^[5] Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. ^[6] Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. ^[7]